ArticleJournal of the Endocrine Society2017
Health Care Burden in Patients With Adrenal Insufficiency.
Article in Journal of the Endocrine Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Effectiveness and safety of continuous subcutaneous hydrocortisone infusion in managing adrenocortical insufficiency in adult patients: a systematic review.Reviews in endocrine & metabolic disorders · 2024Pooled it
- Interventions for the prevention of adrenal crisis in adults with primary adrenal insufficiency: a systematic review.European journal of endocrinology · 2022Pooled it
- Adrenal crises and quality of life after bilateral adrenalectomy vs primary autoimmune adrenal insufficiency.Journal of the Endocrine Society · 2026Article
- What Does Pharmaceutical 3D Printing Cost? A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency.PharmacoEconomics - open · 2025Article
- Using the behaviour change wheel and person-based approach to develop a digital self-management intervention for patients with adrenal insufficiency: theFrontiers in endocrinology · 2023Article
- Quality of Life and its Determinants in Patients With Adrenal Insufficiency: A Survey Study at 3 Centers in the United States.The Journal of clinical endocrinology and metabolism · 2022Article
- Adrenal Insufficiency: Investigating Prevalence and Healthcare Utilization Using Administrative Data.Journal of the Endocrine Society · 2022Article
- Ten-year trends in adrenal insufficiency admissions.Proceedings (Baylor University. Medical Center) · 2022Article
- Determinants of Self-reported Health Outcomes in Adrenal Insufficiency: A Multisite Survey Study.The Journal of clinical endocrinology and metabolism · 2021Article
- The Burden of Hormonal Disorders: A Worldwide Overview With a Particular Look in Italy.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to estimate the annual health care burden for patients with adrenal insufficiency [AI; primary (PAI), secondary to pituitary disorder (PIT), and congenital adrenal hyperplasia (CAH)] using real-world data.
methodsUsing a US-based payer database comprising >108 million members, strict inclusion criteria with diagnostic codes and pharmacy records were used to identify 10,383 patients with AI. This included 1014 patients with PAI, 8818 with PIT, and 551 with CAH, followed for >12 months. Patients were matched 1:1 to controls, based on age (±5 years), sex, insurance, and region. Multivariable expenditure models were estimated for each AI cohort vs controls as well as subsets by glucocorticoid therapy (hydrocortisone, dexamethasone, prednisone, or multiple therapies). A separate multivariable model was estimated to assess the association between adherence and expenditures.
resultsTotal annual health care expenditure estimates were significantly higher (
conclusionPatients with AI demonstrate a substantial annual health care burden. Expenditures vary by underlying cause and treatment and are reduced in patients with higher adherence to glucocorticoid replacement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.